MedTrace Logo

Dosing Intervals of Opioid Medication for Chronic Pain

NCT04132011 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2020-03-27

No results posted yet for this study

Summary

This study is to determine the feasibility of an n-of-1, randomized, double blind, placebo controlled case series to examine effects of extended release opioids when used at intervals shorter than recommended by the manufacturer by people with chronic pain.

Conditions

Interventions

DRUG

Extended Release Opioid Formulation, Shortened Intervals

Extended release opioid, individualized total daily dose, dosing interval is less than every 12 hours

DRUG

Extended Release Opioid Formulation, Standard intervals

Extended release opioid, individualized total daily dose, dosing interval is every 12 hours

DRUG

Placebo oral tablet

Lactose pill manufactured to mimic extended release opioid formulation

Sponsors & Collaborators

  • Canadian Society of Hospital Pharmacists

    collaborator OTHER

  • University Health Network, Toronto

    lead OTHER

Principal Investigators

  • Andrea Furlan, MD, PhD · Principal Investigator

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-01
Primary Completion
2020-03-08
Completion
2020-03-08

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04132011 on ClinicalTrials.gov